Brian Martin, PhD

Senior Scientist II
Castle Biosciences, Inc.
Friendswood, Texas, United States

Presentation(s):

• 62: Prospective validation of the integrated 31-gene expression profile test for cutaneous melanoma to select patients who may consider foregoing sentinel lymph node biopsy

  Thursday, March 21, 2024
  2:17pm – 2:27pm ET